CR11363A - Composicion de zibotentan que contiene manitol y/ o celulosa microcristalina - Google Patents

Composicion de zibotentan que contiene manitol y/ o celulosa microcristalina

Info

Publication number
CR11363A
CR11363A CR11363A CR11363A CR11363A CR 11363 A CR11363 A CR 11363A CR 11363 A CR11363 A CR 11363A CR 11363 A CR11363 A CR 11363A CR 11363 A CR11363 A CR 11363A
Authority
CR
Costa Rica
Prior art keywords
zibotentan
microcrystalline cellulose
manitol
composition
sulfonamide
Prior art date
Application number
CR11363A
Other languages
English (en)
Inventor
John David Blyth
Andrew John Day
Kieran James Lennon
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40534840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11363(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR11363A publication Critical patent/CR11363A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe una composicion farmaceutica que contiene N piridin-3-sulfonamida (es decir, zibotentan o ZD4054)con manitol y/o celulosa microcristalina.
CR11363A 2007-10-12 2010-04-12 Composicion de zibotentan que contiene manitol y/ o celulosa microcristalina CR11363A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97973607P 2007-10-12 2007-10-12
US8911808P 2008-08-15 2008-08-15

Publications (1)

Publication Number Publication Date
CR11363A true CR11363A (es) 2010-07-14

Family

ID=40534840

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11363A CR11363A (es) 2007-10-12 2010-04-12 Composicion de zibotentan que contiene manitol y/ o celulosa microcristalina

Country Status (34)

Country Link
US (2) US8168221B2 (es)
EP (2) EP2209501B1 (es)
JP (1) JP2011500548A (es)
KR (1) KR20100099113A (es)
CN (1) CN101896210A (es)
AR (1) AR068845A1 (es)
AT (1) ATE536893T1 (es)
AU (1) AU2008309385B2 (es)
BR (1) BRPI0818323A2 (es)
CA (1) CA2701385A1 (es)
CL (1) CL2008003022A1 (es)
CO (1) CO6270344A2 (es)
CR (1) CR11363A (es)
CU (1) CU20100064A7 (es)
CY (1) CY1112433T1 (es)
DK (1) DK2209501T3 (es)
DO (1) DOP2010000105A (es)
EA (1) EA201000545A1 (es)
ES (1) ES2377426T3 (es)
HR (1) HRP20120085T1 (es)
IL (1) IL204953A0 (es)
MX (1) MX2010003989A (es)
NI (1) NI201000052A (es)
NZ (1) NZ585310A (es)
PE (1) PE20091032A1 (es)
PL (1) PL2209501T3 (es)
PT (1) PT2209501E (es)
SG (1) SG182138A1 (es)
SI (1) SI2209501T1 (es)
SV (1) SV2010003529A (es)
TW (1) TW200924768A (es)
UY (1) UY31385A1 (es)
WO (1) WO2009047565A2 (es)
ZA (1) ZA201002477B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
KR20100099113A (ko) 2007-10-12 2010-09-10 아스트라제네카 아베 만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물
CN101822796B (zh) * 2010-03-17 2012-01-04 山西仟源制药有限公司 一种银冰含片及制备方法和应用
US9492395B2 (en) * 2010-05-11 2016-11-15 Sensient Colors Llc Film coating composition and methods of making and using the same
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
BR112014026439B1 (pt) * 2012-04-27 2022-05-31 Merck Patent Gmbh Formulação farmacêutica sob a forma de um comprimido revestido, e seu processo de preparação
EP3470397B1 (en) 2012-07-16 2021-12-29 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
SG11201804320QA (en) 2015-12-02 2018-06-28 Nippon Shinyaku Co Ltd Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
WO2021200767A1 (ja) * 2020-03-31 2021-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 錠剤、医薬及びそれらの製造方法並びにキット

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674794A (en) * 1970-03-18 1972-07-04 Ciba Geigy Corp Certain-3-pyridine-sulfonamide derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
TR200202738T2 (tr) * 1997-04-28 2003-03-21 Texas Biotechnology Corporation Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler
CA2374760A1 (en) * 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
MXPA04004476A (es) * 2001-11-13 2004-08-11 Pharmacia Corp Forma de dosificacion oral de un profarmaco la sulfonamida.
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
EP1551401A4 (en) * 2002-09-20 2006-03-22 Merck & Co Inc MANNITOL FORMULATION FOR AN INTEGRIN RECEPTOR ANTAGONIST
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CN101032464A (zh) * 2007-04-01 2007-09-12 杨喜鸿 含有利莫那班和聚乙烯吡咯烷酮的组合物、固体分散体及其制备和药物应用
KR20100099113A (ko) 2007-10-12 2010-09-10 아스트라제네카 아베 만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물

Also Published As

Publication number Publication date
CU20100064A7 (es) 2011-10-05
US20090099203A1 (en) 2009-04-16
CA2701385A1 (en) 2009-04-16
CL2008003022A1 (es) 2010-07-23
PL2209501T3 (pl) 2012-03-30
WO2009047565A2 (en) 2009-04-16
KR20100099113A (ko) 2010-09-10
ATE536893T1 (de) 2011-12-15
EP2209501B1 (en) 2011-12-14
NI201000052A (es) 2011-03-24
EA201000545A1 (ru) 2010-10-29
SI2209501T1 (sl) 2012-03-30
HK1143095A1 (en) 2010-12-24
MX2010003989A (es) 2010-04-27
SG182138A1 (en) 2012-07-30
PE20091032A1 (es) 2009-08-15
DOP2010000105A (es) 2010-08-15
DK2209501T3 (da) 2012-02-27
AU2008309385B2 (en) 2011-10-20
PT2209501E (pt) 2012-02-03
HRP20120085T1 (hr) 2012-02-29
US20120177705A1 (en) 2012-07-12
WO2009047565A3 (en) 2009-11-26
US8168221B2 (en) 2012-05-01
CO6270344A2 (es) 2011-04-20
SV2010003529A (es) 2010-09-13
CN101896210A (zh) 2010-11-24
ES2377426T3 (es) 2012-03-27
UY31385A1 (es) 2009-05-29
BRPI0818323A2 (pt) 2017-05-16
AR068845A1 (es) 2009-12-09
EP2209501A2 (en) 2010-07-28
CY1112433T1 (el) 2015-12-09
IL204953A0 (en) 2010-11-30
JP2011500548A (ja) 2011-01-06
TW200924768A (en) 2009-06-16
AU2008309385A1 (en) 2009-04-16
ZA201002477B (en) 2010-12-29
EP2433620A1 (en) 2012-03-28
NZ585310A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
CU20100064A7 (es) Compisiciones de zibotentan que contienen manitol y/o celulosa microcristalina
CL2007002635A1 (es) Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
CR20110366A (es) Compuesto heterociclico y uso del mismo
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
CL2007001391A1 (es) Compuestos derivados de pirrolidinas sustituidas, inhibidores del factor xa y/o inhibidores sobre la serina proteasa; composicion farmaceutica que comprende a dichos compuestos; proedimiento para preparar la composicon farmaceutica; y uso de los compuestos preparar un medicamneto con un efecto antitrombotico
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
AR059444A1 (es) Composiciones ramnolipidicas y metodos de uso relacionados
CL2008002199A1 (es) Compuestos derivados de 1,3-oxazin-2-ona; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad asociada con la actividad de la 11beta-hidroxiesteroide deshidrogenasa tipo 1 (11beta-hsd1) tales como dislipidemia, hiperlipidemia, hipertension, obesidad y enfermedad cardiovascular, entre otras.
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2007001392A1 (es) Compuestos derivados de quinolina o benzopirano inhibidores de la replicacion del hiv; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una infeccion por vih
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
CL2008003405A1 (es) Compuestos derivados de tienopiridina, inhibidores de la enzima integrasa del vih; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion por vih.
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
AR059445A1 (es) Composiciones de antimicoticos ramnolipidicos y metodos de uso relacionados
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
GT201000037A (es) Depsipéptidos cíclicos
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
BRPI0810399A2 (pt) Composto, composição farmacêutica que o contém e uso do mesmo
CL2009000665A1 (es) Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas.
DOP2010000075A (es) Compuesto inhibidor de glicógeno fosforilasa y composicion farmaceutica del mismo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)